US Pharma MarketingTrump announces nine new drug pricing deals, this time with midsize biotechs
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Nine new companies have announced voluntary drug pricing deals with the White House, looking to avoid industry tariffs and inclusion in two CMS pilot programs under review that are thought to be potentially more financially ...
Source: Endpoints News